Welcome to our dedicated page for Revvity SEC filings (Ticker: RVTY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Revvity, Inc. (NYSE: RVTY) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports on Form 8-K and other key documents filed with the U.S. Securities and Exchange Commission. Revvity, a Massachusetts-incorporated health science and diagnostics company and member of the S&P 500 index, uses these filings to report material events, financial results, and governance changes related to its operations and securities.
Recent Form 8-K filings illustrate how Revvity communicates with the market. The company files 8-Ks to furnish earnings press releases for its quarterly results, to announce preliminary expectations for financial performance, and to provide presentation materials for major investor conferences such as the J.P. Morgan Healthcare Conference. Other 8-Ks disclose board and executive appointments and confirm details about its registered securities, including common stock and notes listed on the New York Stock Exchange.
Through its filings and accompanying earnings materials, Revvity explains the use of non-GAAP financial measures such as adjusted earnings per share, adjusted operating income, and organic revenue growth. The company describes how management uses these measures to evaluate operating performance, benchmark results, and inform compensation decisions, while also outlining the limitations of non-GAAP metrics and providing reconciliations to GAAP figures.
On this page, Stock Titan surfaces Revvity’s SEC filings with real-time updates from EDGAR and AI-powered summaries that clarify the purpose and implications of each document. Users can quickly understand the key points of quarterly results, changes in guidance, capital allocation actions, and governance updates without reading every line of the original filings. Access to these filings, including Form 8-Ks and related exhibits, helps investors, analysts, and researchers track how Revvity reports its financial condition, segment performance, and significant corporate events over time.
Revvity (RVTY) 10-Q – Q2 FY25 highlights
Total revenue rose 4% YoY to $720.3 m, with Life Sciences +5% and Diagnostics +3%. 1H revenue reached $1.39 bn (+3%). Gross margin slipped 123 bp to 54.5% as tariffs and mix offset price increases. SG&A efficiencies trimmed opex, lifting operating income 6% to $90.8 m and widening operating margin 20 bp to 12.6%.
Profitability
- Income from continuing ops fell 24% to $55.2 m; net income dipped 3% to $53.9 m due to lower discontinued-ops losses.
- Diluted EPS held at $0.46 (net) as a 5% share count reduction offset lower earnings.
Cash & Balance Sheet
- Operating cash flow from continuing ops declined 19% to $268.4 m; FCF after capex ≈ $233 m.
- Cash fell to $991.8 m (-15%) after $447.5 m of buybacks and $16.7 m of dividends.
- Long-term debt increased to $3.21 bn; net cash/(debt) now ≈ -$2.22 bn.
Capital returns
- Repurchased 4.43 m shares YTD for $443 m; $414.5 m remains on the $1 bn program.
- Quarterly dividend maintained at $0.07.
Other items: Intangible amortization $85.3 m; FX translation pushed OCI positive by $159 m; no goodwill impairments. Management warns FY25 gross profit could be cut ~$20 m by tariffs despite mitigation efforts.
Takeaway: Top-line momentum is steady and cost control improving operating margin, but core earnings, cash generation and gross margin are under pressure. Heavy buybacks temper EPS erosion while leverage inches higher.